unique opportunity to develop combination regimens that aim to improve 
the lives of patients even further. 
 
   About Roche 
 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics, as well as growing capabilities in the 
area of data-driven medical insights help Roche deliver truly 
personalised healthcare. Roche is working with partners across the 
healthcare sector to provide the best care for each person. 
 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. In recent years, Roche has 
invested in genomic profiling and real-world data partnerships and has 
become an industry-leading partner for medical insights. 
 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2020 employed more than 100,000 people worldwide. 
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 
58.3 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit www.roche.com. 
 
   All trademarks used or mentioned in this release are protected by law. 
 
   References 
 
   [1] GLOBOCAN 2020. World Fact Sheet. [Internet; cited May 2021]. 
Available from: 
http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf 
 
 
   [2] Cancer.Net. Leukemia -- Lymphoma --Non-Hodgkin: Subtype. [Internet; 
cited May 2021]. Available from: 
https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes 
 
   [3] Zhou et al. An enhanced International Prognostic Index (NCCN-IPI) 
for patients with diffuse large B-cell lymphoma treated in the rituximab 
era (NCCN-IPI) Blood. 2014 Feb 6;123(6):837-42 
 
   [4] Carlo Stella C, et al. Glofitamab step-up dosing: updated efficacy 
data show high complete response rates in heavily pretreated 
relapsed/refractory non-Hodgkin lymphoma patients. Poster presented at: 
ASCO Annual Meeting; 2021 Jun 4-8. Abstract #7519. 
 
   [5] Budde E, et al. Promising tolerability and efficacy results from 
dose-escalation in an ongoing Phase Ib/II study of mosunetuzumab with 
polatuzumab vedotin in patients with relapsed/refractory B-cell 
non-Hodgkin's lymphoma. Poster presented at: ASCO Annual Meeting; 2021 
Jun 4-8. Abstract #7520. 
 
   [6] Diefenbach C, et al. Polatuzumab vedotin + rituximab + lenalidomide 
in patients with relapsed/refractory diffuse large B-cell lymphoma: 
primary analysis of a Phase 1b/2 trial Poster presented at: ASCO Annual 
Meeting; 2021 Jun 4-8. Abstract #7512. 
 
   [7] Dornan D, et al. Therapeutic potential of an anti-CD79b 
antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of 
non-Hodgkin lymphoma. Blood 2009;114:2721-29. 
 
   [8] Pfeifer M, et al. Anti-CD22 and anti-CD79B antibody drug conjugates 
are active in different molecular diffuse large B-cell lymphoma 
subtypes. Leukemia 2015;29:1578-86. 
 
   [9] Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic 
payloads to monoclonal antibodies. Bioconjug Chem. 2010;21:5-13. 
 
   [10] ADC Review. What are antibody-drug conjugates? [Internet; cited May 
2021]. Available from: 
 
   https://adcreview.com/adc-university/adcs-101/antibody-drug-conjugates-adcs/ 
 
 
   Roche Group Media Relations 
 
   Phone: +41 61 688 8888 / e-mail: media.relations@roche.com 
https://www.globenewswire.com/Tracker?data=VGYJynlFQGj_5vVwcmgzVF1JmQj087KuVypWxaSQR3M9Q81OB71gXL6f1mJbf1AgYthhXkzdyAecNiwB162e-y2_BoM6aMHNRRBBirKwxstkyZxI0tIBoVjqA3LKvIJm 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: +41 61 687 89 67     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
 
 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: bruno.eschli@roche.com 
 sabine.borngraeber@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  -------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: +1 650 225 3217 
 e-mail: mailto:kalm.loren@gene.com 
 kalm.loren@gene.com 
-------------------------------------------- 
 
 
 
 
   Attachment 
 
 
   -- 04062021_MR_ASCO_immunotherapies in non-Hodgkin lymphoma_en 
      https://ml-eu.globenewswire.com/Resource/Download/53826043-74ff-49d8-b250-fe1201edef44

(END) Dow Jones Newswires

June 04, 2021 08:00 ET (12:00 GMT)